PURPOSE: Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer. MATERIALS AND METHODS: Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) on day 1, and this was repeated every 3 weeks until disease progression. RESULTS: 32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidence interval (CI): 14.2 approximately 48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3 approximately 8.5). The median time to progression was 4.7 months (95% CI: 3.1 approximately 6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%). CONCLUSION: Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted.
PURPOSE: Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer. MATERIALS AND METHODS:Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) on day 1, and this was repeated every 3 weeks until disease progression. RESULTS: 32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidence interval (CI): 14.2 approximately 48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3 approximately 8.5). The median time to progression was 4.7 months (95% CI: 3.1 approximately 6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%). CONCLUSION:Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted.
Authors: Jaffer A Ajani; Miguel B Fodor; Sergei A Tjulandin; Vladimir M Moiseyenko; Yee Chao; Sebastiao Cabral Filho; Alejandro Majlis; Sylvie Assadourian; Eric Van Cutsem Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Keon Woo Park; Jin Seok Ahn; Young Suk Park; Jeeyun Lee; Jung Hoon Kang; Joon Oh Park; Ho Yeong Lim; Young-Hyuck Im; Won Ki Kang; Keunchil Park; Soon Il Lee Journal: Cancer Chemother Pharmacol Date: 2006-05-24 Impact factor: 3.333
Authors: K Ridwelski; T Gebauer; J Fahlke; H Kröning; E Kettner; F Meyer; K Eichelmann; H Lippert Journal: Ann Oncol Date: 2001-01 Impact factor: 32.976
Authors: P Preusser; H Wilke; W Achterrath; U Fink; L Lenaz; A Heinicke; J Meyer; H J Meyer; H Buente Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544
Authors: A D Roth; R Maibach; G Martinelli; N Fazio; M S Aapro; O Pagani; R Morant; M M Borner; R Herrmann; H Honegger; F Cavalli; P Alberto; M Castiglione; A Goldhirsch Journal: Ann Oncol Date: 2000-03 Impact factor: 32.976
Authors: B Glimelius; K Ekström; K Hoffman; W Graf; P O Sjödén; U Haglund; C Svensson; L K Enander; T Linné; H Sellström; R Heuman Journal: Ann Oncol Date: 1997-02 Impact factor: 32.976
Authors: Kassem Barada; Abbas Bitar; Mohamad Abdul-Razak Mokadem; Jana Ghazi Hashash; Peter Green Journal: World J Gastroenterol Date: 2010-03-28 Impact factor: 5.742